Literature DB >> 2228025

A limited role of IL-1 in immune-enhancement by adjuvants.

T Sagara1, S Mori, S Ohkawara, F Goto, K Takagi, M Yoshinaga.   

Abstract

Generation of interleukin-1 (IL-1) in the draining lymph nodes after injection of complete Freund's adjuvant (CFA), incomplete Freund's adjuvant (IFA) and alum was studied in line with IL-1 mRNA expression (cytoplasmic slot blot analysis) and IL-1 beta antigen detection (ELISA and immunohistochemistry) in rabbits. The expression of IL-1 beta mRNA was marked from 6 to 96 hr, with a maximum at around 24 hr post-injection of CFA, while injection of the other two adjuvants elicited only a moderate or negligible response. On the other hand, IL-1 alpha mRNA expression was almost negligible during the entire 8-week observation period after injection of the above three adjuvants. Generation of IL-1 beta antigen in the draining lymph nodes after CFA injection paralleled the expression of IL-1 beta mRNA. Immunohistochemistry revealed that cells containing IL-1 beta resided in the medullary sinuses, marginal sinuses and para-cortical area, but not in the follicles. Despite marked generation of IL-1 beta in CFA-treated draining lymph nodes, the primary antibody response (IgG) to ovalbumin differed only slightly between the three animal groups that were immunized with the antigen incorporated in CFA, IFA and alum. Further, rIL-1 beta did not significantly enhance the immune response when it was entrapped together with the antigen in IFA and alum. IL-1 beta enhanced the immune response only when it was injected with antigen without adjuvant. Thus, IL-1 seemed to play only a limited role, if any, in the augmentation of the primary immune response by the above-mentioned adjuvants.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2228025      PMCID: PMC1384312     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  16 in total

1.  Cloning and characterization of the cDNAs for human and rabbit interleukin-1 precursor.

Authors:  Y Furutani; M Notake; M Yamayoshi; J Yamagishi; H Nomura; M Ohue; R Furuta; T Fukui; M Yamada; S Nakamura
Journal:  Nucleic Acids Res       Date:  1985-08-26       Impact factor: 16.971

Review 2.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.

Authors:  J Le; J Vilcek
Journal:  Lab Invest       Date:  1987-03       Impact factor: 5.662

Review 3.  Interleukin 1: an immunological perspective.

Authors:  S K Durum; J A Schmidt; J J Oppenheim
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

Review 4.  A functional dichotomy in CD4+ T lymphocytes.

Authors:  K Bottomly
Journal:  Immunol Today       Date:  1988-09

5.  Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor.

Authors:  J J Oppenheim; A Togawa; L Chedid; S Mizel
Journal:  Cell Immunol       Date:  1980-03-01       Impact factor: 4.868

Review 6.  Interleukin 2.

Authors:  K A Smith
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

7.  Primary immune response to liposomal tetanus toxoid in mice: the effect of mediators.

Authors:  D Davis; G Gregoriadis
Journal:  Immunology       Date:  1989-10       Impact factor: 7.397

8.  The adjuvanticity of interleukin 1 in vivo.

Authors:  M J Staruch; D D Wood
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

9.  Induction of interleukin 1 secretion by adjuvant-active peptidoglycans.

Authors:  F Vacheron; M Guenounou; C Nauciel
Journal:  Infect Immun       Date:  1983-12       Impact factor: 3.441

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.